DOI: 10.7759/cureus.36794

Review began 03/02/2023 Review ended 03/22/2023 Published 03/28/2023

#### © Copyright 2023

Qureshi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### Retrospective Analysis of Characteristics, Indications and Outcomes of Endoscopic Retrograde Cholangiopancreatography (ERCP) in a Tertiary Referral Center in Saudi Arabia

Laeeque A. Qureshi  $^1$ , Adnan Alzanbagi  $^1$ , Abdulaziz Tashkandi  $^1$ , Mohammed S. Khan  $^1$ , Zaffar M. Malik  $^1$ , Mohammed E. Hefny  $^2$ , Mohammed K. Shariff  $^1$ 

1. Digestive and Liver Center (DLC) and Advanced Endoscopy Center, King Abdullah Medical City, Makkah, SAU 2. DLC & Advanced Endoscopy Center, King Abdullah Medical City, Makkah, SAU

Corresponding author: Laeeque A. Qureshi, laeeque1@yahoo.com

### **Abstract**

Background: Endoscopic retrograde cholangiopancreatography (ERCP) is an advanced endoscopic procedure that is an essential tool in the management of pancreaticobiliary diseases. There is limited data available on the indications and outcomes of ERCP from this region. Therefore, we aim to report the characteristics of patients, indications and outcomes of ERCP in Saudi Arabia.

Methods: We retrospectively looked at ERCP procedures done at a tertiary referral center covering the western region of Saudi Arabia from August 2018 until July 2020. Data were collected from the hospital's electronic patient record and endoscopy database.

Results: Of 1001 ERCPs performed, full data was available on 712 procedures on 581 patients that were included in the final analysis. Mean age was 53.1 years. Four hundred four (56.7%) were female. Board-certified consultants performed all ERCPs. The most common intervention was sphincterotomy, which was performed in 563 (96.9%) patients who underwent first-ever ERCP, followed by dilatation and stenting. The commonest indication of ERCP was confirmed or suspected choledocholithiasis (52.6%), followed by replacement or removal of a biliary stent (15.7%), 55 (7.7%) for suspected ascending cholangitis, 54 (7.5%) for acute biliary pancreatitis and 15 (2%) for suspected sphincter of Oddi dysfunction. The commonest finding among all patients was choledocholithiasis in 57.9%, debris in 15.2% and biliary stricture in 14.8%. The commonest complication was pancreatitis in 22 (3.1%) followed by post-sphincterotomy bleeding in 16 (2.2%) and perforation in nine (1.2%). Bleeding was controlled by endoscopic intervention in four (25%) and one (6.2%) patient underwent surgery. One (0.14%) patient had procedure-related mortality secondary to post-procedure pulmonary embolism and one had significant morbidity and prolonged hospitalization because of complicated perforation. The deeper common bile duct (CBD) cannulation rate was 97.3%.

Conclusion: Our study results revealed that ERCP performed in the western region of Saudi Arabia has similar indications and findings as reported in the international literature. ERCP is successful in achieving the therapeutic objectives with complication rates consistent with published data.

Categories: Internal Medicine, Gastroenterology, Therapeutics

**Keywords:** treatment of cholangiocarcinoma, jaundice, perforation, stent, pancreatitis, bleeding, cbd, ercp, ercp cbd complication bleeding pancreatitis stent

### Introduction

Endoscopic retrograde cholangiopancreatography (ERCP) is an advanced endoscopic procedure that has been an essential tool in the diagnosis and treatment of biliary and pancreatic diseases since its introduction in 1968 [1]. In the past, ERCP was only for diagnostic purposes, but now it is almost exclusively a therapeutic tool. About 350,000-500,000 ERCPs are performed annually in the United States [2]. ERCP is currently the procedure of choice for many pancreaticobiliary diseases. There are multiple indications for ERCP including choledocholithiasis, biliary stricture, primary sclerosing cholangitis, biliary leak, and sphincter of Oddi dysfunction [3]. In addition, ERCP is indicated as a palliative treatment for obstructive jaundice caused by cholangiocarcinoma, or pancreatic cancer [3-4]. ERCP has considerable risks including severe complications and even death. The most common complication of ERCP is pancreatitis, which can happen due to several factors [5-6]. Other complications include cholangitis, cardiopulmonary events mainly due to sedation, bleeding and perforation [5-6]. Overall, the reported post-ERCP morbidity rate is 6.9% and a mortality of 0.3% in the adult population [7]. Globally, several studies were conducted to assess the indications and outcomes of ERCP [8-9]. Apart from a single retrospective study reporting on small numbers, there is limited data about different indications and outcomes of ERCP in Saudi Arabia [10].

Therefore, the aim of our study is to report the characteristics of patients who underwent ERCP at a single

tertiary referral center in the Kingdom of Saudi Arabia (KSA).

### **Materials And Methods**

### Research setting

King Abdullah Medical City (KAMC) is a tertiary healthcare facility in Makkah city, Kingdom of Saudi Arabia (KSA). Digestive and Liver Center (DLC) & Advanced Endoscopy Center (AEC) is one of the busiest units of KAMC, receiving patient from the entire western region of KSA. Approximately 500 ERCP procedures are performed each year.

### Design and study population

This was a retrospective cross-sectional study that included all patients above the age of 18 years who had ERCP performed in DLC & AEC from 2018 to 2020.

### Study outcomes

The primary outcome was to evaluate the common indications and outcomes of patients who underwent ERCP at KAMC. The secondary outcome was to report procedure-related complications including pancreatitis, bleeding, perforation, and cardiopulmonary complications.

### Study procedure

Ethical approval was obtained from King Abdullah Medical City, Makkah institutional review board that has been accredited by the Association for the Accreditation of Human Research Protection Program. The hospital medical e-record system (Track Care, InterSystems) and endoscopy reporting system (Endobase) were searched for all ERCP done during the period of January 2018 to February 2020. Data was collected on (1) Patient demographics (2) ERCP indications (3) Procedural characteristics and findings and (4) All possible intra-procedural and post-procedural complications.

Indications of ERCP were assessed in patients with obstructive jaundice confirmed by pre-procedure investigations including blood work and radiology either ultrasonography (US), computed tomography (CT) scan, or magnetic resonant cholangiopancreatography (MRCP). Written consent was obtained from every patient explaining procedure details, risks, and benefits and all patients were evaluated by anesthesia for sedation or general anesthesia for the procedure.

All ERCP procedures were performed by five board-certified endoscopists who had completed a minimum of 500 bile duct cannulations. The procedures were performed in a dedicated fluoroscopy unit located in the endoscopy department with all sedation provided by a physician anesthesiologist.

### Results

The details of the procedure were documented in the hospital's database (Endobase) by the endoscopist who performed the ERCP. The retrospective analysis of 712 ERCP was made according to the objectives of the study. The baseline characteristics and indications are shown in Table 1.

| Characteristics   | Number of Procedures (%) |
|---|--------------------------|
| Agemean (SD):   | 53.10 (18.93)            |
| Gender:   |                          |
| Women   | 404 (56.7%)              |
| Men   | 308 (43.3%)              |
| Primary indications for ERCP:   |                          |
| Suspected or confirmed stones   | 375 (52.6%)              |
| Replacement or removal of biliary stent   | 81 (11.3%)               |
| Cholangitis   | 55 (7.7%)                |
| Acute biliary pancreatitis  | 54 (7.58%)               |
| Suspected or confirmed stricture  | 43 (6.03%)               |
| Bile Leak   | 36 (5.05%)               |
| Stent placement across strictures, fistula, post-operative bile leak, or large common bile duct stones. | 22 (3.08%)               |
| ? Sphincter of Oddi Dysfunction (SOD)   | 15 (2%)                  |

TABLE 1: Characteristics and indications of endoscopic retrograde cholangiopancreatography (ERCP) (n=712)

They had a mean age of 53 (±18) and 57% of them were women while 43% were men (Figure 1).

## **GENDER FREQUENCY**




FIGURE 1: Gender distribution among patients who underwent endoscopic retrograde cholangiopancreatography (ERCP)

Most patients had ERCP for suspected choledocholithiasis (52.6%) followed by replacement or removal of a biliary stent (15.7%), then cholangitis (7.7%), acute biliary pancreatitis (7.5%), suspected stricture (6.0%), biliary leak (5.0%), stent placement (3.0%), and the least was sphincter of Oddi dysfunction (2%) as shown in Figure 2. The common ERCP-related complications are shown in Table 2.




FIGURE 2: Indications of endoscopic retrograde cholangiopancreatography (ERCP)

SOD: sphincter of Oddi dysfunction

| Characteristics                      | Number of Procedures (%) |
|--------------------------------------|--------------------------|
| Pancreatitis                         | 16 (2.2%)                |
| Bleeding                             | 2 (0.3%)                 |
| Bleeding stooped by:                 |                          |
| Spontaneously                        | 10 (62.5%)               |
| Endoscopic Intervention              | 4 (25%)                  |
| Epinephrine Injection                | 1 (6.25%)                |
| Surgery                              | 1 (6.25%)                |
| Termination of the procedure. Yes No | 1 (6.25%) 15 (93.75%)    |
| Patient needed blood transfusion:    | 4 (25%)                  |
| Patient needed admission to the ICU  | 4 (25%)                  |
| Perforation                          | 2 (0.3%)                 |
| Death                                | 1 (0.1%)                 |

TABLE 2: Incidence of procedure-related complications

Bleeding from the sphincterotomy site was the most overserved ERCP complication; it accounted for 2.2% where 25% of them needed a blood transfusion and admission to the intensive care unit. It was followed by pancreatitis at 0.3% and perforation at 0.3%. Prolonged hospital stay due to a complicated perforation was recorded in one patient (0.1%). Death because of air embolism was reported in one patient (0.1%).

Details of procedural outcomes and characteristics of biliary system are shown in Table 3.

| Characteristics                      | Number of Procedures (%) |
|--------------------------------------|--------------------------|
| Procedural success rate              | 693 (97.3%)              |
| Commonest finding among men & women: |                          |
| Stones (Women)                       | 252 (61%)                |

| ERIPY Stones         375 (57.9%)           Strictures         108 (15.2%)           Debris or sludge         107 (15%)           Pus         30 (4.2%)           Bille Leuk         26 (3.7%)           Bille Leuk         26 (3.7%)           Worms         1 (1.0%)           Successful complete stones extraction         35 44 (3.0%)           Successful complete stones extraction         35 44 (3.0%)           Successful complete stones extraction         11.17 (1.9)           Librotippsy         11 11 (1.9%)           Machanical         10.3 (14.5%)           Laser         6 (0.8%)           Emergency crush         2 (0.3%)           Stent placement/ Replacement         19 (83.2%)           Metallic         32 (16.7%)           Size of stent_mean (SD): (mm)         80.9 (17.3)           Size of stent_mean (SD): (mm)         80.9 (17.3)           Bilary system characteristics:         80.9 (17.3)           With bility system (1.0%)         11.13%)           Fissuard         11 (1.3%)           Finding of at the edge of diverficulum         21 (2.9%)           With Procut         20 (2.8%)           Growth         1 (2.2%)           With Procut         2 (0.3%)                  | Stones (Men)                          | 160 (38.8%)  |
|---|---------------------------------------|--------------|
| Strictures         108 (15.2%)           Debris or sludge         107 (15%)           Cyslic duct stone         37 (8.9%)           Pus         30 (4.2%)           Bile Leak         26 (3.7%)           Fistula         10.1%)           Worms         1 (0.1%)           Successful complete slones extraction         354 (93.9%)           Size of stones_mean (SD): (rmm)         11.47 (11.9)           Lithotripsy         111 (15.6%)           Mechanical         103 (14.5%)           Laser         6 (0.8%)           Emergency crush         2 (0.3%)           Stent placement (Replacement         11 (26.8%)           Type of stent:         191 (26.8%)           Plusatic         159 (83.2%)           Metallic         32 (16.7%)           Size of stent_mean (SD): (mm)         80.91 (7.3)           Billary system characteristics:         30 (1.3%)           Ampulta status         11 (1.3%)           With biliary stent         81 (1.1.3%)           Fiesured         18 (1.1.3%)           Inside or at the edge of diverticulum         21 (2.8%)           With Procut         20 (2.8%)           Growth         6 (0.7%)           Congested  | ERCP findings:                        |              |
| Debris or sludge         107 (15%)           Cysic duct stone         37 (8.9%)           Pus         30 (4.2%)           Bile Leak         26 (3.7%)           Fishula         9 (1.3%)           Worms         1 (0.1%)           Successful complete stones extraction         354 (93.9%)           Size of stones _mean (SD): (mm)         11.47 (11.9)           Lithoripsy         111.47 (11.9)           Laser         6 (0.8%)           Emergency crush         2 (0.3%)           Stent placement/ Replacement         191 (26.8%)           Type of stant:         191 (26.8%)           Plastic         159 (83.2%)           Metallic         32 (16.7%)           Size of stont _moan (SD): (mm)         80.91 (17.3)           Bilary system characteristics:         30.91 (17.3)           Ampulla status         10.11 (1.3%)           With biliary stent         81 (11.3%)           Fissured         31 (4.4%)           Inside or at the edge of diverticulum         21 (2.9%)           With Precut         20 (2.8%)           Growth         16 (2.2%)           Floopy         7 (1%)           Ulcerated         5 (0.7%)           Congested <t< td=""><td>Biliary Stones</td><td>375 (57.9%)</td></t<> | Biliary Stones                        | 375 (57.9%)  |
| Cystic duct stone         37 (8.9%)           Pus         30 (4.2%)           Bile Leak         26 (3.7%)           Fistula         9 (1.3%)           Worms         1 (0.1%)           Successful complete stones extraction         354 (93.9%)           Size of stonesmean (SD): (mm)         111 (15.6%)           Mechanical         103 (4.5%)           Laser         6 (0.8%)           Emergency crush         2 (0.3%)           Stent placement (Replacement         191 (26.8%)           Type of stent:         191 (26.8%)           Pleaste         159 (83.2%)           Metallic         32 (16.7%)           Size of stentmean (SD): (mm)         30.91 (71.3%)           Billary system characteristics:  | Strictures                            | 108 (15.2%)  |
| Pus         30 (4.2%)           Bile Leak         26 (3.7%)           Fistula         9 (1.3%)           Worms         1 (0.1%)           Successful complete stones extraction         354 (83.9%)           Size of stones _mean (SD): (mm)         114 (11.9)           Lithotripicy         111 (15.6%)           Mechanical         103 (14.5%)           Laser         6 (0.8%)           Emergency crush         2 (0.3%)           Sizent placement? Replacement         191 (25.8%)           Type of stent:         191 (25.8%)           Plastic         159 (83.2%)           Metallic         32 (16.7%)           Size of stent _mean (SD): (mm)         80.91 (17.3)           Biliary system characteristics:         24.00           Ampulla status         27.00           With Dillary stent         81 (11.3%)           Fisured         31 (4.4%)           Inside or at the edge of diverticulum         21 (2.9%)           With Precut         20 (2.8%)           Growth         16 (2.2%)           Filoppy         7 (1%)           Ulcerated         2 (0.3%)           Swollen         1 (0.1%)           Not Seen or reached         19 (2.7%)  | Debris or sludge                      | 107 (15%)    |
| Bile Leak         26 (3.7%)           Fistula         9 (1.3%)           Worms         1 (0.1%)           Successful complete stones extraction         354 (93.9%)           Size of stones _mean (SD): (mm)         11 47 (11.9)           Lilhotripsy         111 (15.5%)           Mechanical         103 (14.5%)           Laser         6 (0.8%)           Emergency crush         2 (0.3%)           Stent placement/ Replacement         191 (26.8%)           Type of silent:         191 (26.8%)           Plastic         159 (83.2%)           Metallic         32 (16.7%)           Size of stent _mean (SD): (mm)         80.91 (17.3)           Plastic of stent _mean (SD): (mm)         80.91 (17.3)           With biliary system characteristics:         10.00 (17.5%)           With biliary stent         81 (11.3%)           Fissured         31 (4.4%)           Inside or at the edge of diverticulum         21 (2.9%)           With Precut         20 (2.8%)           Growth         16 (2.2%)           Filoppy         1 (1.0%)           Ulcerated         2 (0.3%)           Swollen         1 (0.1%)           Not Seen or reached         19 (2.7%)   | Cystic duct stone                     | 37 (8.9%)    |
| Fibilal         9 (1.3%)           Worms         1 (0.1%)           Successful complete stones extraction         364 (83.9%)           Size of stones_mean (SD): (mm)         11.47 (11.9)           Lithotripsy         111 (15.6%)           Mechanical         103 (14.5%)           Laser         6 (0.8%)           Emergency crush         2 (0.3%)           Stent placement         191 (26.8%)           Type of stent:         ************************************  | Pus                                   | 30 (4.2%)    |
| Womes         1 (0.1%)           Successful complete stones extraction         354 (93.9%)           Size of stones_mean (SD): (mm)         11.47 (11.9)           Lithotripsy         111 (15.6%)           Mechanical         103 (14.5%)           Laser         6 (0.8%)           Emergency crush         2 (0.3%)           Stent placement         191 (26.8%)           Type of stent:         ************************************   | Bile Leak                             | 26 (3.7%)    |
| Size of stones _mean (SD): (mm)         11.47 (11.9)           Lithotripsy         111 (15.6%)           Mechanical         103 (14.5%)           Laser         6 (0.8%)           Emergency crush         2 (0.3%)           Stent placement/ Replacement         191 (26.8%)           Type of stent:   | Fistula                               | 9 (1.3%)     |
| Size of stones_mean (SD): (mm)         11.47 (11.9)           Lithotripsy         111 (15.6%)           Mechanical         103 (14.5%)           Laser         6 (0.8%)           Emergency crush         2 (0.3%)           Stent placement Replacement         191 (26.6%)           Type of stent:   | Worms                                 | 1 (0.1%)     |
| Lihotripsy         111 (15.6%)           Mechanical         103 (14.5%)           Laser         6 (0.8%)           Emergency crush         2 (0.3%)           Stent placement Replacement         191 (26.8%)           Type of stent:         """"""""""""""""""""""""""""""""""""   | Successful complete stones extraction | 354 (93.9%)  |
| Mechanical         103 (14.5%)           Laser         6 (0.8%)           Emergency crush         2 (0.3%)           Stent placement Replacement         191 (26.8%)           Type of stent:         """"""""""""""""""""""""""""""""""""  | Size of stonesmean (SD): (mm)         | 11.47 (11.9) |
| Laser         6 (0.8%)           Emergency crush         2 (0.3%)           Stent placement/ Replacement         191 (26.8%)           Type of stent:         159 (83.2%)           Plastic         32 (16.7%)           Metallic         32 (16.7%)           Size of stent_mean (SD): (mm)         80.91 (17.3)           Billiary system characteristics:         80.91 (17.3)           Ampulla status         509 (71.5%)           With biliary stent         81 (11.3%)           Fissured         31 (4.4%)           Inside or at the edge of diverticulum         21 (2.9%)           With Precut         20 (2.8%)           Growth         16 (2.2%)           Floppy         7 (1%)           Ulcerated         5 (0.7%)           Congested         2 (0.3%)           Swollen         1 (0.1%)           Not Seen or reached         1 (0.1%)           CBD status:         101           Dilated         412 (67.8%)           Normal         207 (41.7%)           Tortuous         3 (0.4%)   | Lithotripsy                           | 111 (15.6%)  |
| Emergency crush         2 (0.3%)           Stent placement/ Replacement         191 (26.8%)           Type of stent:         159 (83.2%)           Plastic         32 (16.7%)           Metallic         32 (16.7%)           Size of stent_mean (SD): (mm)         80.91 (17.3)           Billiary system characteristics:   | Mechanical                            | 103 (14.5%)  |
| Stent placement/ Replacement         191 (26.8%)           Type of stent:         159 (83.2%)           Plastic         159 (83.2%)           Metallic         32 (16.7%)           Size of stent _mean (SD): (mm)         80.91 (17.3)           Billiary system characteristics:  | Laser                                 | 6 (0.8%)     |
| Type of stent:         159 (83.2%)           Metallic         32 (16.7%)           Size of stent_mean (SD): (mm)         80.91 (17.3)           Billiary system characteristics:  | Emergency crush                       | 2 (0.3%)     |
| Plastic       159 (83.2%)         Metallic       32 (16.7%)         Size of stent_mean (SD): (mm)       80.91 (17.3)         Biliary system characteristics:       ————————————————————————————————————   | Stent placement/ Replacement          | 191 (26.8%)  |
| Metallic       32 (16.7%)         Size of stent_mean (SD): (mm)       80.91 (17.3)         Biliary system characteristics:  | Type of stent:                        |              |
| Size of stentmean (SD): (mm)       80.91 (17.3)         Biliary system characteristics:         Ampulla status         Normal       509 (71.5%)         With biliary stent       81 (11.3%)         Fissured       31 (4.4%)         Inside or at the edge of diverticulum       21 (2.9%)         With Precut       20 (2.8%)         Growth       16 (2.2%)         Floppy       7 (1%)         Ulcerated       5 (0.7%)         Congested       2 (0.3%)         Swollen       1 (0.1%)         Not Seen or reached       19 (2.7%)         CBD status:       Dilated       412 (57.8%)         Normal       297 (41.7%)       3 (0.4%)         Tortuous       3 (0.4%)  | Plastic                               | 159 (83.2%)  |
| Billiary system characteristics:       Ampulla status         Normal       509 (71.5%)         With biliary stent       81 (11.3%)         Fissured       31 (4.4%)         Inside or at the edge of diverticulum       21 (2.9%)         With Precut       20 (2.8%)         Growth       16 (2.2%)         Floppy       7 (1%)         Ulcerated       5 (0.7%)         Congested       2 (0.3%)         Swollen       1 (0.1%)         Not Seen or reached       19 (2.7%)         CBD status:       207 (41.7%)         Normal       412 (57.8%)         Normal       207 (41.7%)         Tortuous       3 (0.4%)   | Metallic                              | 32 (16.7%)   |
| Ampulla status           Normal         509 (71.5%)           With biliary stent         81 (11.3%)           Fissured         31 (4.4%)           Inside or at the edge of diverticulum         21 (2.9%)           With Precut         20 (2.8%)           Growth         16 (2.2%)           Floppy         7 (1%)           Ulcerated         5 (0.7%)           Congested         2 (0.3%)           Swollen         1 (0.1%)           Not Seen or reached         19 (2.7%)           CBD status:         297 (41.7%)           Normal         297 (41.7%)           Tortuous         3 (0.4%)   | Size of stentmean (SD): (mm)          | 80.91 (17.3) |
| Normal         509 (71.5%)           With biliary stent         81 (11.3%)           Fissured         31 (4.4%)           Inside or at the edge of diverticulum         21 (2.9%)           With Precut         20 (2.8%)           Growth         16 (2.2%)           Floppy         7 (1%)           Ulcerated         5 (0.7%)           Congested         2 (0.3%)           Swollen         1 (0.1%)           Not Seen or reached         19 (2.7%)           CBD status:         Dilated         412 (57.8%)           Normal         297 (41.7%)           Tortuous         3 (0.4%)           CHD status:  | Biliary system characteristics:       |              |
| With biliary stent       81 (11.3%)         Fissured       31 (4.4%)         Inside or at the edge of diverticulum       21 (2.9%)         With Precut       20 (2.8%)         Growth       16 (2.2%)         Floppy       7 (1%)         Ulcerated       5 (0.7%)         Congested       2 (0.3%)         Swollen       1 (0.1%)         Not Seen or reached       19 (2.7%)         CBD status:       297 (41.7%)         Normal       297 (41.7%)         Tortuous       3 (0.4%)         CHD status:       20 (2.8%)   | Ampulla status                        |              |
| Fissured       31 (4.4%)         Inside or at the edge of diverticulum       21 (2.9%)         With Precut       20 (2.8%)         Growth       16 (2.2%)         Floppy       7 (1%)         Ulcerated       5 (0.7%)         Congested       2 (0.3%)         Swollen       1 (0.1%)         Not Seen or reached       19 (2.7%)         CBD status:       297 (41.7%)         Tortuous       3 (0.4%)         CHD status:       412 (57.8%)  | Normal                                | 509 (71.5%)  |
| Inside or at the edge of diverticulum       21 (2.9%)         With Precut       20 (2.8%)         Growth       16 (2.2%)         Floppy       7 (1%)         Ulcerated       5 (0.7%)         Congested       2 (0.3%)         Swollen       1 (0.1%)         Not Seen or reached       19 (2.7%)         CBD status:       297 (41.7%)         Normal       297 (41.7%)         Tortuous       3 (0.4%)         CHD status:       4 (2.5%)   | With biliary stent                    | 81 (11.3%)   |
| With Precut       20 (2.8%)         Growth       16 (2.2%)         Floppy       7 (1%)         Ulcerated       5 (0.7%)         Congested       2 (0.3%)         Swollen       1 (0.1%)         Not Seen or reached       19 (2.7%)         CBD status:       412 (57.8%)         Normal       297 (41.7%)         Tortuous       3 (0.4%)         CHD status:  | Fissured                              | 31 (4.4%)    |
| Growth       16 (2.2%)         Floppy       7 (1%)         Ulcerated       5 (0.7%)         Congested       2 (0.3%)         Swollen       1 (0.1%)         Not Seen or reached       19 (2.7%)         CBD status:       412 (57.8%)         Normal       297 (41.7%)         Tortuous       3 (0.4%)         CHD status:       412 (57.8%)  | Inside or at the edge of diverticulum | 21 (2.9%)    |
| Floppy       7 (1%)         Ulcerated       5 (0.7%)         Congested       2 (0.3%)         Swollen       1 (0.1%)         Not Seen or reached       19 (2.7%)         CBD status:       Torluos         Dilated       412 (57.8%)         Normal       297 (41.7%)         Tortuous       3 (0.4%)         CHD status:   | With Precut                           | 20 (2.8%)    |
| Ulcerated       5 (0.7%)         Congested       2 (0.3%)         Swollen       1 (0.1%)         Not Seen or reached       19 (2.7%)         CBD status:       412 (57.8%)         Normal       297 (41.7%)         Tortuous       3 (0.4%)         CHD status:       412 (57.8%)   | Growth                                | 16 (2.2%)    |
| Congested       2 (0.3%)         Swollen       1 (0.1%)         Not Seen or reached       19 (2.7%)         CBD status:       412 (57.8%)         Normal       297 (41.7%)         Tortuous       3 (0.4%)         CHD status:       412 (57.8%)  | Floppy                                | 7 (1%)       |
| Swollen       1 (0.1%)         Not Seen or reached       19 (2.7%)         CBD status:  | Ulcerated                             | 5 (0.7%)     |
| Not Seen or reached       19 (2.7%)         CBD status:          Dilated       412 (57.8%)         Normal       297 (41.7%)         Tortuous       3 (0.4%)         CHD status:   | Congested                             | 2 (0.3%)     |
| CBD status:         Dilated       412 (57.8%)         Normal       297 (41.7%)         Tortuous       3 (0.4%)         CHD status:       CHD status:  | Swollen                               | 1 (0.1%)     |
| Dilated       412 (57.8%)         Normal       297 (41.7%)         Tortuous       3 (0.4%)         CHD status:       Tortuous   | Not Seen or reached                   | 19 (2.7%)    |
| Normal 297 (41.7%) Tortuous 3 (0.4%) CHD status:  | CBD status:                           |              |
| Tortuous 3 (0.4%) CHD status:   | Dilated                               | 412 (57.8%)  |
| CHD status:   | Normal                                | 297 (41.7%)  |
|   | Tortuous                              | 3 (0.4%)     |
| Normal 515 (72.3%)  | CHD status:                           |              |
|   | Normal                                | 515 (72.3%)  |

| Dilated                 | 101 (14.1%) |
|-------------------------|-------------|
| Not seen                | 77 (10.8%)  |
| IHD status:             |             |
| Normal                  | 531 (74.6%) |
| Dilated                 | 101 (14.1%) |
| Beaded                  | 8 (1 %)     |
| Pancreatic duct status: |             |
| Normal                  | 81 (11.4%)  |
| Dilated                 | 19 (2.7%)   |

# TABLE 3: Outcomes of endoscopic retrograde cholangiopancreatography (ERCP) and characteristics of biliary system.

CBD: common bile duct; CHD: common hepatic duct; IHD: intrahepatic bile duct

Outcomes include the findings on cholangiogram such as stones, strictures, or bile leak and successful biliary stone removal or stent placement etc. Success of procedure is considered as rate of deeper common bile duct (CBD) cannulation and was achieved in 97.3% of cases. The commonest finding among men and women is the biliary stone, either intra- or extrahepatic or inside cystic duct or gall bladder. It is followed by debris or sludges (15.2%), strictures (12.1%), pus (4.2%), biliary leak (3.2%), and fistula (1.2%). Complete stones extraction was successful in 354 (93.9%) cases. The characteristics of the biliary system include ampullary position and shape, size and shape of CBD, common hepatic duct (CHD), intra-hepatic duct (IHD), and cystic ducts and pancreatic duct in selected cases.

### **Discussion**

ERCP has shown and emphasized its importance as a therapeutic tool for many pancreaticobiliary diseases including common problems such as choledocholithiasis [3]. To accurately determine how much ERCP is an appropriate tool, it's important to report and review the most updated data regarding the possible complications and outcomes. The present study is evaluating the different aspects of ERCP, i.e. common indications and outcomes and biliary characteristics of patients who underwent ERCP in our center.

As shown by different reports around the world, suspected or confirmed stones is the most frequent indication for ERCP [10-12]. The latest study was published in 2020 and it was at a Canadian tertiary center that showed 61% of patients who had ERCP is for suspected or confirmed stones followed by suspected or confirmed strictures [10], which is the same in this region too. Similarly, the rate of complications is comparable to the reported results in the same study. By looking at Figure 2, choledocholithiasis is still the most frequently reported indication, followed by replacement or removal of a biliary stent as the most probable cause of obstruction. In another report from Finland, palliative ERCP for pancreaticobiliary malignancies is the second commonest indication [11], also noted same in our study.

Determining precisely the procedure's risk factors and implementing the appropriate measures such as pharmacological measures to reduce the rate of ERCP-related pancreatitis is an important step to prevent ERCP-related complications which eventually is going to impact the outcomes in a positive way [12]. According to multiple reports, pancreatitis is the most commonly observed complication followed by bleeding and perforation [12]. Cardiopulmonary complications and death are the lowest observed complications [12]. In the present study, pancreatitis is the second reported ERCP-related complication where intra-operative bleeding is the commonest seen complication. With the surgical risks and adverse events especially among the elderly and those who have co-morbidities, ERCP has been showing its safety and efficacy with a relatively low rate of complications [13]. Cardiopulmonary complications and death are the lowest reported and the overall ERCP-related mortality rate is 0.1%. It was a result of air embolism, which is potentially life-threatening but also, it's a rare complication.

By comparing ERCP findings among men and women, it appears that women are more at risk of having choledocholithiasis than men. This explains the higher number of female patients undergoing ERCP.

There are some limitations to the study where further details such as BMI, type of sedative or non-steroidal anti-inflammatory drugs (NSAIDs) that were used, and cannulation time haven't been reported because they were missing and not documented for some patients.

### **Conclusions**

ERCP is a useful therapeutic procedure that has shown promise in treating a variety of pancreaticobiliary disorders, particularly those with significant surgical risk. As a result of the procedure's invasiveness, problems can arise. Prior to the treatment, patients with advanced comorbid conditions should have a thorough evaluation. Data from our center is almost similar as reported from other centers. An advanced endoscopist, anesthesiologists, gastrointestinal nurses, and a hepatobiliary surgeon can all work together as a multidisciplinary team to improve the procedure's safety, outcomes, and success.

### **Additional Information**

### **Disclosures**

**Human subjects:** All authors have confirmed that this study did not involve human participants or tissue. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

#### **Acknowledgements**

I am very thankful to the administration of King Abdullah Medical City for their support, especially the members of the advanced endoscopy center, anesthesia team, IRB and paramedical staff. I would like to thank my colleague consultants Dr Saad Zahrani, Dr Yaser K Meeralam, Dr Mona Alsaedi and Dr Mohammed El Hefny for their sincere advises during my work.

### References

- Maple JT, Ikenberry SO, Anderson MA, et al.: The role of endoscopy in the management of choledocholithiasis. Gastrointest Endosc. 2011, 74:731-44. 10.1016/j.gie.2011.04.012
- Cappell MS, Friedel DM: Stricter national standards are required for credentialing of endoscopic-retrogradecholangiopancreatography in the United States. World J Gastroenterol. 2019, 25:3468-83. 10.3748/wjg.v25.i27.3468
- Chathadi KV, Chandrasekhara V, Acosta RD, et al.: The role of ERCP in benign diseases of the biliary tract.
   Gastrointest Endosc. 2015, 81:795-803. 10.1016/j.gie.2014.11.019
- Anderson MA, Appalaneni V, Ben-Menachem T, et al.: The role of endoscopy in the evaluation and treatment of patients with biliary neoplasia. Gastrointest Endosc. 2013, 77:167-74. 10.1016/j.gie.2012.09.029
- Rustagi T, Jamidar PA: Endoscopic retrograde cholangiopancreatography-related adverse events: general overview. Gastrointest Endosc Clin N Am. 2015, 25:97-106. 10.1016/j.giec.2014.09.005
- Bilbao MK, Dotter CT, Lee TG, et al.: Complications of endoscopic retrograde cholangiopancreatography (ERCP): a study of 10,000 cases. Gastroenterology. 1976, 70:314-20. 10.1016/S0016-5085(76)80139-4
- Andriulli A, Loperfido S, Napolitano G, et al.: Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol. 2007, 102:1781-8.
- Khafaf A, Rad N, Alizadeh AM: Evaluating the outcomes of endoscopic retrograde cholangiopancreatography: indications and complications. Ann Med Health Sci Res. 2019, 9:529-35.
- Forbes N, Koury HF, Bass S, et al.: Characteristics and outcomes of ERCP at a Canadian tertiary centre: initial results from a prospective high-fidelity biliary endoscopy registry. J Can Assoc Gastroenterol. 2021, 4:78-83. 10.1093/jcag/gwaa007
- Abbarh S, Seleem M, Al Balkhi A, et al.: ERCP quality indicators: the experience of a high-volume tertiary care center in Saudi Arabia. Arab J Gastroenterol. 2019, 20:32-7. 10.1016/j.ajg.2019.01.005
- Siiki A, Tamminen A, Tomminen T, Kuusanmäki P: ERCP procedures in a Finnish community hospital: a retrospective analysis of 1207 cases. Scand J Surg. 2012, 101:45-50. 10.1177/145749691210100109
- 12. Katsinelos P, Lazaraki G, Chatzimavroudis G, et al.: Risk factors for therapeutic ERCP-related complications: an analysis of 2,715 cases performed by a single endoscopist. Ann Gastroenterol. 2014, 27:65-72.
- Yıldırım AE, Öztürk ZA, Konduk BT, et al.: The safety and efficacy of ERCP in octogenarians: a comparison of two geriatric age cohorts. Acta Gastroenterol Belg. 2017, 80:263-70.